Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PTPRA | P18433 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990892 | 0.81 | CYP1A2 (0.44) | SMN1; SMN2POLBCYP1A2CYP2D6MAPT | |
| SCHEMBL1990894 | 0.81 | CYP1A2 (0.44) | SMN1; SMN2POLBCYP1A2CYP2D6MAPT | |
| SCHEMBL20330203 | 0.81 | POLB (0.48) | SMN1; SMN2POLBCYP1A2CYP2D6MAPT | |
| SCHEMBL9911543 | 0.80 | CYP1A2 (0.54) | SMN1; SMN2POLBCYP1A2CYP2D6MAPT | |
| SCHEMBL7336481 | 0.78 | PTPRA (0.57) | SMN1; SMN2POLBCYP1A2CYP2D6MAPT | |
| SCHEMBL7481222 | 0.78 | PTPRA (0.57) | SMN1; SMN2POLBCYP1A2CYP2D6MAPT | |
| SCHEMBL6122738 | 0.78 | HPGD (0.47) | SMN1; SMN2POLBCYP1A2TSHRALDH1A1 | |
| SCHEMBL834974 | 0.77 | POLB (0.50) | POLBCYP1A2TSHRALDH1A1RAB9A | |
| SCHEMBL4473658 | 0.77 | POLB (0.50) | POLBCYP1A2TSHRALDH1A1RAB9A | |
| SCHEMBL1991963 | 0.77 | POLB (0.50) | POLBCYP1A2TSHRALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873704-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2016-11-17 | — | — | US | disclosed |
| EP-2445900-B1 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | AMGEN INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8765768-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| EP-2640715-A1 | QUINOLINE DERIVATIVES AS PIK3 INHIBITORS | Amgen Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130231352-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2513109-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012068343-A1 | QUINOLINE DERIVATIVES AS PIK3 INHIBITORS | AMGEN INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2445900-A2 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KEAP1 2702/4885NFE2L2 1490/4885SMN1; SMN2 983/4885 |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KEAP1 2254/4885NFE2L2 1613/4885SMN1; SMN2 912/4885 |
| US-20130231352-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, SSB | KEAP1 1482/4885NFE2L2 841/4885SMN1; SMN2 239/4885 |
| US-20160333017-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KEAP1 2667/4885NFE2L2 1463/4885SMN1; SMN2 989/4885 |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | KEAP1 2667/4885NFE2L2 1463/4885SMN1; SMN2 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.